Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nippon Chemiphar’s Generics Business Continues To Recover

As Japanese Company Sees 2.4% Growth In Generics Segment

Executive Summary

Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic. 

You may also be interested in...



Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery

Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”

Nippon Chemiphar Turns The Tide With Increase In Generics Sales

Japan’s Nippon Chemiphar has reported a year-on-year increase in generics sales and net revenues in the first quarter of FY21, after seeing back-to-back underwhelming quarters due to reasons such as recent National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.

Nichi-Iko Slashes Profitability Guidance As Supply Issues Drag On

Nichi-Iko has been forced to cut dramatically its core operating profit guidance for its 2022 financial year, as it continues to deal with the fallout of its previously deficient Namerikawa manufacturing facility in the Toyama prefecture.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel